Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Storb

Showing results (301-310 of 315) with videos related to

Pageof 32
Sort By:
The Lancet. Haematology|June 29, 2019
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trialBrenda M Sandmaier, Brian Kornblit, Barry E Storer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemiaBoglarka Gyurkocza, Rainer Storb, Barry E Storer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2007
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemiaDaniella M B Kerbauy, Theodore A Gooley, George E Sale, et al.
Blood|December 10, 2008
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di MidolloBenedetto Bruno, Marcello Rotta, Francesca Patriarca, et al.
Blood|August 1, 2002
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeH Joachim Deeg, Barry Storer, John T Slattery, et al.
Blood|August 16, 2003
Allogeneic hematopoietic stem cell transplantation for myelofibrosisH Joachim Deeg, Theodore A Gooley, Mary E D Flowers, et al.
Blood|June 28, 2007
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningChristoph Kahl, Barry E Storer, Brenda M Sandmaier, et al.
Blood|May 24, 2003
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosisRichard A Nash, James D Bowen, Peter A McSweeney, et al.
Blood|April 25, 2007
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash, Peter A McSweeney, Leslie J Crofford, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimenH Joachim Deeg, Barry E Storer, Michael Boeckh, et al.
Pageof 32

Showing results (301-310 of 315) with videos related to

Sort By:
Pageof 32
The Lancet. Haematology|June 29, 2019
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trialBrenda M Sandmaier, Brian Kornblit, Barry E Storer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemiaBoglarka Gyurkocza, Rainer Storb, Barry E Storer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2007
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemiaDaniella M B Kerbauy, Theodore A Gooley, George E Sale, et al.
Blood|December 10, 2008
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di MidolloBenedetto Bruno, Marcello Rotta, Francesca Patriarca, et al.
Blood|August 1, 2002
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeH Joachim Deeg, Barry Storer, John T Slattery, et al.
Blood|August 16, 2003
Allogeneic hematopoietic stem cell transplantation for myelofibrosisH Joachim Deeg, Theodore A Gooley, Mary E D Flowers, et al.
Blood|June 28, 2007
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningChristoph Kahl, Barry E Storer, Brenda M Sandmaier, et al.
Blood|May 24, 2003
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosisRichard A Nash, James D Bowen, Peter A McSweeney, et al.
Blood|April 25, 2007
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash, Peter A McSweeney, Leslie J Crofford, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimenH Joachim Deeg, Barry E Storer, Michael Boeckh, et al.
Pageof 32